Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1360460-82-7

Anlotinib is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1360460-82-7 Suppliers

This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.
  • 1360460-82-7 Structure

  • Basic information

    1. Product Name: Anlotinib
    2. Synonyms: Anlotinib HCl;Anlotinib 2HCl
    3. CAS NO:1360460-82-7
    4. Molecular Formula: C23H24Cl2FN3O3
    5. Molecular Weight: 480.3593632
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1360460-82-7.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Anlotinib(CAS DataBase Reference)
    10. NIST Chemistry Reference: Anlotinib(1360460-82-7)
    11. EPA Substance Registry System: Anlotinib(1360460-82-7)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1360460-82-7(Hazardous Substances Data)

1360460-82-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1360460-82-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,0,4,6 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1360460-82:
(9*1)+(8*3)+(7*6)+(6*0)+(5*4)+(4*6)+(3*0)+(2*8)+(1*2)=137
137 % 10 = 7
So 1360460-82-7 is a valid CAS Registry Number.

1360460-82-7Downstream Products

1360460-82-7Relevant articles and documents

Anlotinib hydrochloride intermediate and preparation method of anlotinib hydrochloride

-

, (2019/11/04)

The invention provides an anlotinib hydrochloride intermediate and a preparation method of anlotinib hydrochloride. 4-hydroxy-6-methoxyl-7-GO substituted quinolone and 2-fluorine-3-halogenate-6-bitrotoluene are used for generating 4-(2-fluorine-3-methyl-4

Method for preparing anlotinib hydrochloride

-

, (2019/05/28)

The invention discloses a method for preparing anlotinib hydrochloride. The method has the advantages that 7-benzyloxy-4-chlorine-6-methoxyquinoline compounds 1 and 1-(2-fluorine-3-hydroxyl-6-nitrophenyl) propyl-2-ketone compounds 2 are used as starting m

Quinoline derivative impurity as well as preparation method and application thereof

-

Paragraph 0045-0046, (2018/03/24)

The invention provides a quinoline derivative impurity as well as a preparation method and application thereof and in particular relates to an impurity of a compound of formula I as shown in the specification, and a preparation method and application of the impurity. The impurity of the compound of the formula I, which is provided by the invention, can be used as a reference marker for detection on the impurity of the compound of the formula I, the compound of the formula I and the content of the impurity of a preparation of the compound can be effectively and conveniently monitored, the compound of the formula I and the quality of the preparation of the compound can be controlled, and the security and the effectiveness of the compound of the formula I and the preparation of the compound can be ensured.

Method for synthesizing anlotinib and hydrochloride thereof

-

Paragraph 0033-0034; 0044-0046, (2018/12/14)

The invention relates to a method for synthesizing anlotinib and hydrochloride thereof. Specifically, the method comprises steps (1) to (3) and step (4) or (5) in the description. According to the method disclosed by the invention, a technological flow is

Quinoline derivatives and preparation method for the crystallization of the

-

Paragraph 0054-0063, (2018/02/04)

The invention relates to a crystal of a quinoline derivative, a preparation method of the crystal, a pharmaceutical composition comprising the crystal and application of the pharmaceutical composition in the field of medicine, in particular to three crystalline solid manners of quinoline derivative dihydrochloride, namely an A-type crystal, a B-type crystal and a C-type crystal, wherein the A-type crystal and the B-type crystal are crystals basically not containing crystal water molecules and other solvents, and the C-type crystal is the crystal containing two crystal water molecules.

Spiro Substituted Compounds As Angiogenesis Inhibitors

-

Page/Page column 20, (2008/12/07)

The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.